



Press release

Sensorion will present two posters at the Association for Research in Otolaryngology ARO 46th Annual MidWinter Meeting

Montpellier, February 2, 2023 – Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce its participation, in-person, in the Association for Research in Otolaryngology (ARO) 46th Annual MidWinter Meeting, taking place on February 11-15, 2023, in Orlando, Florida, United States.

Laurent Désiré, PhD, Preclinical Development Director, and Arnaud Giese, PhD, Group Leader - Animal Pharmacology Platform, will co-present two posters during the **Association for Research in Otolaryngology (ARO) 46th MidWinter Meeting**, taking place on February 11-15, 2023, in Orlando, Florida, United States. The poster abstracts are accessible by entering their title on the ARO MidWinter Meeting [website](#):

- **“Preclinical Development of an Adeno-Associated Vector-Based Gene Therapy (SENS-501) for the Autosomal Recessive Non-Syndromic Deafness 9 (DFNB9)”**
- **“An Integrated Adeno-Associated Vector Development Platform for Inner Ear Disorders”**

Furthermore, Arnaud Giese, PhD, will co-chair a podium session entitled **“Inner Ear Therapeutics”**. The session will take place on February 12, 2023, 8 am – 10 am EST (2 pm – 4 pm CET), in the Crystal Ballroom D-E.

The agenda of the conference can be found [here](#).

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.

Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. Its portfolio combines both small molecule and inner ear gene therapies programs.

Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 Proof of Concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

Sensorion pursues its broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by mutations of the gene encoding for otoferlin, and hearing loss related to mutations in *GJB2* gene to potentially address important hearing loss segments in adults and children (GJB2-GT). The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

www.sensorion.com

Press release

Contacts

Investor Relations

Noemie Djokovic
Investor Relations and Communications
+33 6 76 67 98 31
ir.contact@sensorion-pharma.com

International Media Relations

Consilium Strategic Communications
Matthew Cole/Jessica Hodgson
+44 7593 572720
+44 7561 424788
Sensorion@consilium-comms.com

Label: **SENSORION**
ISIN: **FR0012596468**
Mnemonic: **ALSEN**



Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2021 full year financial report published on April 28, 2022, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.